ArticleCurrent medical imaging2025
Liver Functions in Patients with Chronic Liver Disease and Liver Cirrhosis: Correlation of FLIS and LKER with PALBI Grade and APRI.
Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn chronic liver disease (CLD) and liver cirrhosis (LC), assessing hepatic function and disease severity is crucial for patient management. This study aimed to evaluate the relationship between platelet-albumin-bilirubin (PALBI) grade and aspartate aminotransferase/platelet ratio index (APRI) with the functional liver imaging score (FLIS) and liver-to-kidney enhancement ratio (LKER) using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced hepatobiliary phase (HBP) magnetic resonance imaging (MRI).
methodsAfter applying exclusion criteria, 86 patients with CLD or LC who underwent Gd-EOB-DTPA-enhanced MRI between January 2018 and October 2023 were included. APRI and PALBI grades were calculated from laboratory data. FLIS was determined as the sum of three HBP imaging features (liver parenchymal enhancement, biliary excretion, and portal vein sign), with each scoring 0-2. LKER was calculated by dividing liver signal intensity by kidney intensity using region of interest (ROI) measurements. Spearman's correlation was used to assess relationships between the variables.
resultsAPRI showed a weak negative correlation with both FLIS (r = -0.327, p = 0.02) and LKER (r = -0.308, p = 0.004). PALBI showed a moderate negative correlation with FLIS (r = -0.495, p = 0.001) and LKER (r = -0.554, p = 0.0001). DISCUSSION: FLIS and LKER moderately correlated with PALBI and weakly with APRI. LKER may be a more practical tool due to its quantitative nature. Despite limitations, combining imaging and lab-based scores could enhance liver function assessment.
conclusionFLIS and LKER can validate, rather than predict or exclude, liver dysfunction in CLD and LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.